{"id":"W4296468436","doi":"10.1016/s2152-2650(22)01379-9","title":"CML-395 Efficacy and Safety Results From ASCEMBL, a Phase III Study of Asciminib vs. Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): Week 96 Update","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Bosutinib; Medicine; Discontinuation; Adverse effect; Internal medicine; Imatinib; Oncology; Gastroenterology; Myeloid leukemia; Nilotinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003410979,0.0006638676,0.001620306,0.0004792865,0.0003114904,0.001872449,0.001161132,0.001144286,0.004970499],"category_scores_gemma":[0.003263068,0.0002785083,0.001921453,0.0007910437,0.0002521648,0.0009319258,0.0004112851,0.002910495,0.001748674],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001799896,"about_ca_system_score_gemma":0.001591504,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002036642,"about_ca_topic_score_gemma":0.005862534,"domain_scores_codex":[0.9991565,0.0002261675,0.00009840787,0.00009707956,0.000335304,0.00008655326],"domain_scores_gemma":[0.9975281,0.0007344197,0.0007543727,0.0001095544,0.0004851237,0.0003883848],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.08714826,0.002865421,0.01483579,0.004700086,0.004094463,0.0001996073,0.0001993674,0.00227103,0.01203266,0.001122923,0.1254513,0.745079],"study_design_scores_gemma":[0.1394136,0.06178043,0.1684186,0.003961936,0.01172158,0.001754994,0.000197281,0.00237034,0.009439603,0.002658816,0.598052,0.0002308167],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.4376467,0.3548529,0.004322845,0.02336944,0.002235891,0.0025288,0.09654276,0.001082725,0.07741796],"genre_scores_gemma":[0.6957823,0.1362477,0.007155052,0.02440439,0.003013814,0.002399085,0.1045064,0.0003935607,0.02609762],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004970499,"threshold_uncertainty_score":0.01803923,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01787776851328367,"score_gpt":0.3041802002471399,"score_spread":0.2863024317338563,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}